I-PET / CT isekela isigaba seHodgkin Lymphoma ngakumbi ngokuchanekileyo
I-lymphomas yile khansela equka iintlobo zeeseli ezimhlophe zegazi ezibizwa ngokuba yi-lymphocytes. I-lymphomas ngokuqhelekileyo ibalwa njengeHodgkin okanye i-non-Hodgkin lymphomas .
Kukho iintlobo ezintlanu zeHodgkin lymphoma, okanye i-HL. Ixesha eliqhelekileyo le -HL libhekiselele kwiintlobo ezine eziqhelekileyo ezilandelayo: i-nodular sclerosing HL, i-cellularity HL, i-lymphocyte-rich-classic HL kunye ne-lymphocyte-ephelile i-HL.
Uhlobo lwesihlanu luyi-HL-lymphocyte-predominant HL, kwaye ayithathwa njenge-classic HL.
Iimpawu . Abantu abane-HL bangahlakulela iimpawu ezahlukileyo, kodwa uphawu oluqhelekileyo luya kwandisa i-lymph node okanye enye into. I-lymph nodes ingakhutshwa entanyeni, emanzini, okanye e-groin, okanye ngaphakathi kwesifuba. Ngokuqhelekanga, abo abaneHodgkin lymphoma, okanye i-HL, banokuphelelwa kwesisindo, umkhuhlane, ukubetha okanye ukugubungela ebusuku. Ubukho bezinye zezi zimpawu zifaneleke njengeziphumo zeB.
Izinto zobungozi . Ukuba nemingcipheko ayithethi ukuba uya kufumana i-HL. Enyanisweni, abantu abaninzi abane-HL abanalo mingcipheko eyaziwayo. Iziganeko zobungozi ezibandakanya i- mononucleosis, okanye i-mono ; amaqela angamaqondo angamaqondo angama-age e-HL angama-20s no-70s / 80; Imbali yentsapho; imvelaphi ephakamileyo yoluntu; kunye noGawulayo.
Ukuxilongwa kunye nokuThengisa . Ngokutsho kwe-American Cancer Society, oogqirha banokukhetha kwiindlela ezahlukeneyo zokuthatha isampuli yezinto ezibandakanyekayo, okanye i-biopsy, ukuvavanya nokuhlalutya.
Xa i-PET / CT itholakala, isetyenziswe kwisiteji. Iziphumo ze-PET / CT zidibanisa i-CT kunye ne-PET, okanye i-positron emission tomography ukufumana ukuba umhlaza usasazeke kangakanani kwaye nokuba lukhulu kangakanani.
Mayelana ne-PET kunye ne-PET / CT
I-PET isebenzisa ifom e-radioactive yeshukela, okanye i-FDG, ethatyathwa, ngokubanzi, ngama-cell i-Hodgkin lymphoma kakuhle, okanye njengakliniki zithi, ngokukhawuleza.
Ngokwe-physics, uhlobo lwe-radiation lufana nelo x-rays, nangona kunjalo, ukuhluthwa okuhlangeneyo ukusuka kwi-PET-CT kukuba malunga namaxesha angama-10 ukuya phezulu kune-exposure kwi-x-ray rhoqo. Ukutshekisha okunjalo kudibaniswa neenzuzo ezinokubakho kodwa kubangelwa ubungozi obuvela kwi-dose enkulu yombane kunye nomngcipheko womhlaza. Ngaloo ndlela, umlinganiselo wengozi-mali kufuneka ulinganiswe ngokucophelela ngamnye ngamnye ngaphambi kokufunda.
Ukutshekisha kwe-PET ngokuqhelekileyo kunesifo ngakumbi kune-CT ekufumaneni i-lymphoma. Ngokomzekelo, i-PET ingabonisa izifo kwi-lymph nodes eziqhelekileyo kwaye zincede zihlolisise izifo ezingaphandle kweelymode, kodwa zingabonakali kwi-CT. I-PET idla ngokuhlanganiswa ne-CT ukuvumela ukuthelekiswa kwemimandla yomsakazo ophezulu kwi-PET yokutshekisha ngokubonakala kwenkcazo yendawo kule CT. Xa kuthelekiswa neengcamango eziqhelekileyo, ukusetyenziswa kwe-PET / CT kwisiseko kunokuba nefuthe kumagqabantshintshi kwaye kukhokelela kunyango olulodwa kwinani elikhulu lamatyala.
I-PET / CT yeHodgkin Lymphoma
Izikhokelo ezivela kwiNational National Comprehensive Cancer Network zincoma ukusetyenziswa kwe-PET / CT ukulungiselela isisombululo sokuqala nokuvavanywa kokugqibela kwezigulane ezine-HL. Ngenxa yokuba i-PET / CT iyilungele ukuhlolwa kweempendulo kunye nokuphendula impendulo ngexesha nangemva kwonyango, isetyenziselwa ukuzama ukuphucula ukonyango.
Xa izigulane ezininzi zibandakanyeka kwiimvavanyo zonyango, ukuhlolwa kwesikhashana kungasetyenziselwa iintlobo ezahlukeneyo zesifo, kuquka i-HL, ukuzama ukuchaza kwangaphambili imfuneko yonyango ehlukile kodwa ayikhuthazwa ngokwangoku okwangoku.
I-PET / CT iyinto enhle ekufumaneni i-lymph node ezibandakanyekile neHodgkin lymphoma. Kukulungele ukufumana isifo kwindawo yomnxeba nakwezinye izitho. Isigaba se-HL sincike kwinani nendawo yokubandakanya i-lymph nodes kunye nezinye izakhiwo ezibandakanyekayo. Ucwaningo luye lwabonisa ukuba amandla angakumbi okufumanisa i-PET / CT ikhokelela kuma-10 ukuya kwe-15 ekhulwini lwezigulane ezine-HL ezitshintshela kwisigaba esiphezulu-esiphezulu ngakumbi, oko kukuthi, kunokuba isetyenziswe ngu-CT, yedwa.
Ngoko, izigulane ezininzi zifumana unyango abayidingayo.
Ngonyango lwamayeza olucwangciswe rhoqo kwizigulane ze-HL zeziganeko zokuqala, i-PET / CT inokunye inzuzo. Kwezinye iimeko, ukuchongwa ngokuchanekileyo kweendawo ezibandakanyekayo okanye izixhobo ezinokuthi kuncedise oogqirha abacwangcisa unyango lwe-radiation ukuba bagxilise ummandla omncinci, onokuba nefuthe elingaphantsi kwezicubu ezinempilo.
I-PET / CT kwiNyango kunye neNgcebiso
I-Hodgkin lymphoma yenye yeendidi ezininzi ze-lymphoma ezibhekwa njengezona ziphilisa kakhulu. Ukubukwa kwesitembu sokunyuselwa kwesifo apho i-lymphoma ikhona kwaye ikhula-ibaluleke kakhulu kwi-HL, kungekhona nje ngokuba inceda ukucacisa isigqibo sonyango, kodwa ngenxa yokuba inceda ukuqikelela ukuxela kwangaphambili.
Izigulane ezinezifo ezisekuqaleni zifumana unyango lwe-radiation kuphela, ngelixa zizifo eziphambili, i-chemotherapy inikezelwa kwaye imisebe ingasetyenziselwa ngakumbi izifo ezitshatyalaliswayo, ngokwe-Hutchings kunye noogxa.
Izigulane zabantu abadala abanesifo esisisigxina basesigxina esingaphezu kweepesenti ezingama-90 kwizilingo ezininzi. Kwizifo eziphambili, ukusinda ngokubanzi ngama-65-80 ekhulwini. Kuzo zombini izigaba kunye nezifo eziphambili, ukuqokelela ngokubanzi ngokubhekiselele kwimingcipheko yenziwa rhoqo.
Ukongeza kwi-staging echanekileyo, i-PET / CT inokukunceda ukufumanisa nasiphi na isifo esala emva kwonyango. Oku kunokuba luncedo, umzekelo, xa kukho ubunzima bokusalela, okanye ukwandiswa kwisifuba kwaye akucaci ukuba kubonakala ukuba kubonakala isifo esinqabileyo okanye esisebenzayo.
> Imithombo:
> I-American Cancer Society. Ziziphi iingxaki zobungozi beHodgkin?
> Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma. J Natl Compr Canc Netw . 2011; 9 (9): 1020-1058.
> Hutchings M. Uncedo lwe-PET / CT njani ekukhetheni unyango kwizigulane ngeHodgkin lymphoma? I-Hematology I-Soc Hematol yoLwazi lweNkqubo . 2012; 2012: 322-7.
> I-Townsend W, iLinch D. Hodgkin's lymphoma kubantu abadala. Lancet . 2012; 380 (9844): 836-47.